Phase 2
Completed N=13
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
Source: ClinicalTrials.gov NCT00345293 ↗Enrolled (actual)
13
Serious AEs
15.4%
Results posted
Apr 2016
Primary outcomePrimary: Toxicity — 2; 204 events
Summary
The purpose of this study is to assess the safety and activity of DC/PC3, a dendritic cell vaccine used as immunotherapy for prostate cancer. The vaccine is made with each participants' own immune cells obtained through blood donation. Dendritic cells are known to activate other immune cells such as T cells, that are able to mount an attack against cancer cells. The dendritic cell vaccine will be administered as injections every 2 weeks over a course of 2 months.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Toxicity |
2; 204 | — |
| SECONDARY Immunogenicity |
62; 9461 | — |
| SECONDARY Clinical Response |
— | — |
Eligibility Criteria
Inclusion Criteria
Prostate cancer
Rising prostate specific antigen (PSA, 3 values, each measured at least 2 weeks apart) post initial therapy (ie, radiation, prostatectomy) human leukocyte antigen A2.1 (HLA-A2.1)
-
Exclusion Criteria
central nervous system metastasis
History of autoimmune disease
Data sourced from ClinicalTrials.gov (NCT00345293). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.